期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不能分类的骨髓增生异常/骨髓增殖性疾病转化为急性髓系白血病2例并文献复习 被引量：3

Two cases of myelodysplastic/myeloproliferative neoplasms-unclassified evolving into acute myelogenous leukemia and literature review
原文传递
导出
摘要 目的:探讨不能分类的骨髓增生异常/骨髓增殖性疾病(MDS/MPN-U)的临床特点、诊断、治疗及预后。方法:对2例MDS/MPN-U的临床资料进行分析总结,并结合近年来国内外文献进行讨论。结果:MDS/MPN-U具有混合性MPN和MDS特征而不能归为任何一种MDS、MPN或MDS/MPN亚型,高风险转化为急性髓系白血病,化疗及放疗效果较差,生存期较短。结论:MDS/MPN-U是一类少见的血液系统恶性疾病,其最终可能发展为急性髓系白血病。 Objective：To explore the clinic feature,diagnose,treatment and prognosis of myelodysplastic/myeloproliferative neoplasms-unclassified（MDS/MPN-U）. Method：Two patients with MDS/MPN-U were reported and related literature were reviewed. Result：MDS/MPN-U showed features of both MDS and MPN but didn＇t meet the criteria for any of the three major MDS/MPN entities,with higher-risk evolving into acute myelogenous leukemia,poor response to radiation therapy and chemotherapy and shorter life expectancy. Conclusion：MDS/MPN-U is a kind of rare malignant diseases which may progress to become acute myelogenous leukemia.
作者 黎建云 涂传清 唐玫琴 张旭艳 王典文
机构地区 深圳市宝安人民医院血液科
出处 《临床血液学杂志》 CAS 2013年第4期474-476,共3页 Journal of Clinical Hematology
关键词 骨髓增生异常综合征 不能分类的骨髓增生异常 骨髓增殖性疾病 急性髓系白血病 myelodysplastic syndromes myelodysplastic/myeloproliferative neoplasms-unclassified acute myelogenous leukemia
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1VARDIMAN J W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms[J]. Chem Biol Interact, 2010, 184:16-20.
  • 2CANNELLA L, BRECCIA M, LATAGLIATA R, et al. Clinical and prognostic features of patients with myelodysplastie/myeloproliferative syndrome catego- rized as unclassified (MDS/MPD-U) by WHO classi- fication[J]. Leuk Res, 2008,32 : 514- 516.
  • 3THEPOT S, ITZYKSON R, SEEGERS V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syn- drome or acute myeloid leukemia by azacitidine:a re- port on 54 cases on the behalf of the Groupe Franco phone des Myelodysplasies (GFM) [J]. Blood, 2010, 116:3735-3742.
  • 4BEJANYAN N,TIU R V,RAZA A,et al. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbie acid (TADA) in patients with overlap myelodysplastie/myeloprolif- erative neoplasms (MDS/MPN) or primary myelofi- brosis (PMF) [M]. Cancer, 2012,118 : 3968- 3976.
  • 5CHUNG E,HSU C L,KONDO M,et al. Constitutive MAP kinase activation in hematopoietic stem cells in- duces a myeloproliferative disorder [J]. PLoS One, 2011,6 .. e28350.

同被引文献33

  • 1Vardiman JW,Imber M,Pierre R,et al.In:Jaffe ES,Harris NL,Stein H,Vardiman JW (eds).world health organization classification of tumours:tumours of the haematopoietic and lymphoid tissues.International agency for research on cancer (IARC)[M].Press:Lyon,France,2001,58-59.
  • 2Vardiman JW,Harris NL,Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms[J].Blood,2002,100 (7):2292-2302.
  • 3Swerdlow SH,Campo E,Harris N L,et al.(eds).WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues[M].4th ed.Lyon:IARC,2008,75-86.
  • 4Vardiman JW,Thiele J,Arber DA,et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J].Blood,2009,114 (5):937-951.
  • 5Tefferi A,Vardiman JW.Classification and diagnosis of myeloproliferative neoplasms:The 2008 world health organization criteria and pointof-care diagnostic algorithms[J].Leukemia,2008,22 (1):14-22.
  • 6Orazi A.Germing U.The myelodysplastic/myeloproliferative neoplasms:myeloproliferative diseases with dysplastic features[J].Leukemia,2008,22 (7):1308-1319.
  • 7Malcovati L,Cazzola M.Myelodysplastic/myeloproliferative disorsers[J].Haematologica,2008,93 (1):4-6.
  • 8G ǎman M,Vl d ǎeanu AM,Onisai M.Refractory anemia with ring sideroblasts associated with marked thrombocytosis:case report and literature review[J].Rom J Morphol Embryol,2012,53 (3):645-650.
  • 9Broséus J,Alpermann T,Wulfert M,et al.Age,JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis[J].Leukemia,2013,27 (9):1826-1831.
  • 10Gurevich I,Luthra R,Konoplev SN,et al.Refractory anemia with ring sideroblasts associated with marked thrombocytosis:a mixed group exhibiting a spectrum of morphologic findings[J].Am J Clin Pathol,2011,135 (3):398-403.

引证文献3

二级引证文献4

临床血液学杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部